Benchmarking health technology assessment agencies-methodological challenges and recommendations

被引:3
作者
Wang, Ting [1 ,2 ]
Lipska, Iga [1 ,2 ,3 ]
McAuslane, Neil [1 ]
Liberti, Lawrence [1 ]
Hovels, Anke [2 ]
Leufkens, Hubert [2 ]
机构
[1] Ctr Innovat Regulatory Sci, London, England
[2] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[3] Natl Hlth Fund, Warsaw, Poland
关键词
Health technology assessment; Benchmarking tool; Medicines; RELATIVE EFFECTIVENESS ASSESSMENTS; HTA; DECISIONS; MEDICINES;
D O I
10.1017/S0266462320000598
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives The objectives of the study were to establish a benchmarking tool to collect metrics to enable increased clarity regarding the differences and similarities across health technology assessment (HTA) agencies, to assess performance within and across HTA agencies, identify areas in the HTA processes in which time is spent and to enable ongoing performance improvement. Methods Common steps and milestones in the HTA process were identified for meaningful benchmarking among agencies. A benchmarking tool consisting of eighty-six questions providing information on HTA agency organizational aspects and information on individual new medicine review timelines and outcomes was developed with the input of HTA agencies and validated in a pilot study. Data on 109 HTA reviews from five HTA agencies were analyzed to demonstrate the utility of this tool. Results This study developed an HTA benchmarking methodology, comparative metrics showed considerable differences among the median timelines from assessment and appraisal to final HTA recommendation for the five agencies included in this analysis; these results were interpreted in conjunction with agency characteristics. Conclusions It is feasible to find consensus among HTA agencies regarding the common milestones of the review process to map jurisdiction-specific processes against agreed metrics. Data on characteristics of agencies such as their scope and remit enabled results to be interpreted in the appropriate local context. This benchmarking tool has promising potential utility to improve the transparency of the review process and to facilitate both quality assurance and performance improvement in HTA agencies.
引用
收藏
页码:332 / 348
页数:17
相关论文
共 26 条
  • [1] Allen N, 2017, FRONT PHARMACOL, V8, P834
  • [2] Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland
    Allen, Nicola
    Walker, Stuart R.
    Liberti, Lawrence
    Salek, Sam
    [J]. VALUE IN HEALTH, 2017, 20 (03) : 320 - 328
  • [3] [Anonymous], 2015, CONCEPTOS REV FILOSO, V8, P13
  • [4] Best practice in undertaking and reporting health technology assessments -: Working group 4 report
    Busse, R
    Orvain, J
    Velasco, M
    Perleth, M
    Drummond, M
    Gürtner, F
    Jorgensen, T
    Jovell, A
    Malone, J
    Rüther, A
    Wild, C
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2002, 18 (02) : 361 - 422
  • [5] Cai J, 2018, R D BRIEFING 69 REV
  • [6] Centre for Innovation in Regulatory Science (CIRS), 2018, REG REIMB ATL
  • [7] Drummond M, 2002, INT J TECHNOL ASSESS, V24, P244
  • [8] CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?
    Drummond, Michael
    Neumann, Peter
    Jonsson, Bengt
    Luce, Bryan
    Schwartz, J. Sanford
    Siebert, Uwe
    Sullivan, Sean D.
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (02) : 159 - 165
  • [9] European Commission, 2018, IMP ASS STRENGTH EU
  • [10] TOWARD INTERNATIONAL GOOD PRACTICES IN HEALTH TECHNOLOGY ASSESSMENT
    Goodman, Clifford
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (02) : 169 - 170